Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited - pharma in Pune City, Maharashtra, India. FY 2026 financials & compliance.
CIN L24231PN1981PLC024251 Incorporated 16 April 1981 ROC Pune HQ Pune City, Maharashtra, India
Active Listed Public Limited Company pharma
Data last updated
Market Cap
₹37,033 Cr
EMCURE · NSE
Share Price
₹1,950.60
-0.08% today
Revenue
₹9,204 Cr
FY 2025-26 · +16.3% YoY
EBITDA
₹1,714 Cr
Margin 18.6%
Net Profit
₹945 Cr
FY 2025-26 · +48.3% YoY
P/E (TTM)
36.5x
P/B 7.6x
ROE
20.0%
ROCE 23.1%
Debt / Equity
0.27
Interest cover 11.1x

About Emcure Pharmaceuticals Limited

Data last updated: 25 September 2026

Emcure Pharmaceuticals Limited is a public limited company based in Pune City, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 April 1981, the company has been in operation for over 45 years.

Registered with ROC Pune under CIN L24231PN1981PLC024251. Listed.

Capital: an authorised share capital of ₹250 Cr and a paid-up capital of ₹189.66 Cr. Formerly known as Emcure Pharmaceuticals Private Limited. It is led by directors including Palamadai Sundararajan Jayakumar and Shailesh Kripalu Ayyangar.

Last AGM: 28 August 2025. Financial statements filed for year ended 31 March 2025. Office: Bt Park, Pune City, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹9,203.54 Cr, a growth of 16.56% compared to the previous year. The net worth stands at ₹4,950.03 Cr (up 11.33% YoY). Total assets are valued at ₹6,608.99 Cr (up 9.79% YoY).

The company has a workforce of approximately 6,877 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 3 brands - Chiral Emcure, Emcure, Gennova. As per MCA filings, the company has open charges of ₹1,655.61 Cr and satisfied charges of ₹7,259.14 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website emcure.co.in.

Company Details of Emcure Pharmaceuticals Limited
CIN L24231PN1981PLC024251
Registration Number 024251
Incorporation Date 16 April 1981
ROC Pune
Listing Status Listed
Company Status Active
Date of Last AGM 28 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Satish Ramanlal Mehta Managing Director Mukund Keshao Gurjar Whole-Time Director Sunil Rajanikant Mehta Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    emcure.co.in
  • Social Media
  • Registered Address
    Plot No. P – 1 & P – 2 It – Bt Park, Phase – Ii M.I.D.C., Pune City, Maharashtra, India – 411057
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Company report
Emcure Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Emcure Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Emcure Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24231PN1981PLC024251. The current CIN is L24231PN1981PLC024251, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24231PN1981PLC024251 Current
U24231PN1981PLC024251 Previous

Associated Brands with Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited operates multiple associated brands including Chiral Emcure, Emcure, and Gennova. These brands represent Emcure Pharmaceuticals Limited's diversified market presence and brand portfolio.

Brand Description Website
Chiral Emcure
Research and manufacturing of pharmaceutical APIs, formulations, and biotechnology products globally. chiralemcure.com
Emcure
Developer, manufacturer, and markets a broad range of pharmaceutical products emcure.com
Gennova
Biotherapeutics for life-threatening diseases are developed, produced, and commercialized. gennova.bio

Competitors & Alternatives of Emcure Pharmaceuticals Limited

Brands and companies operating in the same space as Emcure Pharmaceuticals Limited include Senti Biosciences, Ardelyx, Concord Biotech and 7 more.

Competitor Description Location Founded
Senti Biosciences Senti Biosciences Cell-based therapies for cancer treatment are developed. San Francisco, United States, United States 2016
Ardelyx Ardelyx Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. Fremont, United States, United States 2007
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
Tenaya Therapeutics Tenaya Therapeutics Regenerative and gene therapeutics for heart failure are developed. San Francisco, United States, United States 2016
Orca Bio Orca Bio Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders Menlo Park, United States, United States 2016
Adicet Bio Adicet Bio Immune cell therapies for cancer treatment are developed. Menlo Park, United States, United States 2014
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured. Mumbai, India, India 2003
Calliditas Therapeutics Calliditas Therapeutics Provider of small molecule based drug for inflammatory kidney disease Stockholm, Sweden, Sweden 2004
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
DermBiont DermBiont Microbial therapeutics for skin diseases are developed. Melrose, United States, United States 2015

Business Activity of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Emcure Pharmaceuticals Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is audited by B S R & Co. Llp for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
B S R & Co. Llp Locked Locked Locked
Premium access

Complete auditor history for Emcure Pharmaceuticals Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is currently managed by 11 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Palamadai Sundararajan Jayakumar
Also directs: Ht Media Limited, Adani Ports And Special Economic Zone Limited, Northern Arc Capital Limited and 5 more
Director 22 Jul 2020 6 Years 2 Months Current
Shailesh Kripalu Ayyangar
Also directs: Gennova Biopharmaceuticals Limited, Zuventus Healthcare Limited, Shaily Engineering Plastics Limited and 2 more
Director 16 Apr 2021 5 Years 5 Months Current
Satish Ramanlal Mehta
Also directs: Emcutix Biopharmaceuticals Limited, Zuventus Healthcare Limited
Managing Director 16 Apr 1981 45 Years 5 Months Current
Mukund Keshao Gurjar Whole-Time Director 23 Jul 2001 25 Years 2 Months Current
Berjis Minoo Desai
Also directs: Berjis Desai Capital Advisor Llp, Jupiter Metaverse Llp, Berjis Desai Iconic Brands Llp and 5 more
Director 03 Apr 1997 29 Years 5 Months Current
Vijay Keshav Gokhale
Also directs: Zuventus Healthcare Limited, Kpit Technologies Limited
Director 16 Apr 2021 5 Years 5 Months Current
Showing 6 of 11 current directors. View all directors

Financials of Emcure Pharmaceuticals Limited FY 2025-26 filings available

Emcure Pharmaceuticals Limited reported revenue of ₹9,203.54 Cr (up 16.56% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,204 Cr
+16.6% YoY
EBITDA
₹1,714 Cr
+17.5% YoY
Profit After Tax
₹945 Cr
+48.3% YoY
Net Worth
₹4,950 Cr
+11.3% YoY
Total Assets
₹6,609 Cr
+9.8% YoY
Total Debt
₹1,521 Cr
+48.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.3%+18.4%+13.1%+6.3%+12.8%-9.8%+8.7%
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Profit before tax1,287971727747973652105
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Balance sheet
Total assets6,6096,0205,8115,0894,4454,9664,686
Net worth4,9504,4462,9522,5011,9882,2731,912
Total debt1,5211,0232,3352,3342,2172,3102,327
Cash & bank148165232458313524164
Net working capital2,7072,3872,1022,2921,8481,9151,429
Cash flow
Cash from operations9448521,097747768704500
Cash from investing(1,175)(96.05)(715)(468)(574)(256)(168)
Cash from financing343(814)(164)(145)(152)(189)(301)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,5802,4702,3632,2702,1012,1161,9632,002
Revenue growth (YoY)+22.9%+16.7%+20.4%+13.4%+15.7%+19.5%+17.7%+20.4%
Other income2.0714.291.853.123.704.453.9035.65
EBITDA532480455475413392355381
EBITDA margin+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%+19.0%
Depreciation11010610510599.4696.8496.8196.90
Interest31.5446.4037.9832.5426.7639.0331.7846.22
Profit before tax394341314341291261230273
Tax10197.4482.4290.0575.9763.3773.8371.86
Net profit292244231251215197156202
EPS (₹)15.5012.8412.1612.8510.929.978.1210.23
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+13.0%+22.6%+14.6%+3.2%+6.8%+21.6%+4.1%
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Profit before tax944428200212616557225
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
Balance sheet
Total assets5,3723,9383,5933,6673,4264,0113,202
Net worth3,7113,0241,9351,8421,7132,3021,915
Total debt1,5978571,5951,7731,5791,6651,243
Cash & bank16.8813.8032.1214147.8826139.22
Net working capital1,5031,0089881,2201,2741,3921,170
Cash flow
Cash from operations424558585505428775385
Cash from investing(947)(438)(173)(271)(394)(836)(169)
Cash from financing526(49.25)(288)(54.52)(343)30.97(45.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,4511,4681,4181,2611,0971,2781,0291,105
Revenue growth (YoY)+32.3%+14.8%+37.9%+14.1%+13.0%+41.6%+18.2%+24.4%
Other income25.0334.5213822.7521.5222.4019.4149.06
Total expenses1,1111,0961,1471,0368721,034904947
EBITDA340372271225224245124158
EBITDA margin+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%+14.3%
Depreciation63.1763.0462.1461.7459.8256.9156.6556.34
Interest32.7836.8733.1527.7120.5424.0719.9331.40
Profit before tax26930631415816618667.24119
Tax68.5772.5755.5140.2742.8846.4917.0532.44

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,5802,4702,3632,2702,1012,1161,9632,002
Revenue growth (YoY)+22.9%+16.7%+20.4%+13.4%+15.7%+19.5%+17.7%+20.4%
Other income2.0714.291.853.123.704.453.9035.65
EBITDA532480455475413392355381
EBITDA margin+20.6%+19.4%+19.2%+20.9%+19.7%+18.5%+18.1%+19.0%
Depreciation11010610510599.4696.8496.8196.90
Interest31.5446.4037.9832.5426.7639.0331.7846.22
Profit before tax394341314341291261230273
Tax10197.4482.4290.0575.9763.3773.8371.86
Net profit292244231251215197156202
EPS (₹)15.5012.8412.1612.8510.929.978.1210.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,2047,8966,6585,9865,8555,0335,049
Revenue growth+16.3%+18.4%+13.1%+6.3%+12.8%-9.8%+8.7%
Other income13172.7956.9945.9163.4733.8882.31
Total expenses7,4896,4385,4384,8114,5254,0104,448
Employee cost1,5521,4461,2921,1171,0129031,106
EBITDA1,7141,4581,2201,1751,3301,023600
EBITDA margin+18.6%+18.5%+18.3%+19.6%+22.7%+20.3%+11.9%
Depreciation415384312260245250321
Interest144176237214176155257
Profit before tax1,287971727747973652105
Tax3462642001852702334.73
Net profit945638504537662421159
Net profit margin+10.3%+8.1%+7.6%+9.0%+11.3%+8.4%+3.2%
EPS (₹)48.7635.9627.5029.4236.6223.154.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus4,7604,2572,7712,3201,8072,0921,731
Shareholders' funds (net worth)4,9504,4462,9522,5011,9882,2731,912
Minority interest26.6419516914912794.9972.41
Secured loans1,2047301,7231,8831,8001,9552,513
Unsecured loans317293612452418355(187)
Total debt1,5211,0232,3352,3342,2172,3102,327
Total liabilities6,6096,0205,8115,0894,4454,9664,686
Assets
Gross block5,9525,4385,0523,8023,4723,2493,523
Net block3,3193,1973,1252,1472,0442,1882,382
Capital work in progress273177159411320302485
Investments19.7095.3831825.0025.000.000.00
Inventories2,3981,9321,5251,3831,4491,5141,173
Sundry debtors2,5632,0021,8591,6481,3091,4751,145
Cash & bank balances148165232458313524164
Loans & advances504380344346353204221
Total current assets5,6124,4803,9603,8363,4243,7172,703
Total current liabilities2,9052,0931,8581,5441,5761,8021,274
Net working capital2,7072,3872,1022,2921,8481,9151,429
Total assets6,6096,0205,8115,0894,4454,9664,686
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(14.31)43.99(175)(308)(350)(609)(641)
Net cash from operating activities9448521,097747768704500
Net cash from investing activities(1,175)(96.05)(715)(468)(574)(256)(168)
Net cash from financing activities343(814)(164)(145)(152)(189)(301)
Net change in cash112(58.30)21913441.8725931.86
Closing cash148165232458313524164
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.6%+18.6%+11.2%+2.2%+16.3%-0.3%+7.0%
EBITDA growth+17.6%+19.6%+3.8%-11.7%+30.0%+70.4%-4.1%
PBT growth+32.5%+33.6%-2.7%-23.2%+49.2%+519.1%-68.1%
Net income growth+48.3%+26.6%-6.2%-19.0%+57.2%+165.2%-21.6%
Revenue CAGR (3Y)+15.4%+10.5%+9.8%+5.8%+7.5%--
EBITDA CAGR (3Y)+13.4%+3.1%+6.0%+25.1%+28.6%--
Profitability & leverage
Net income margin+10.2%+9.0%+7.9%+9.4%+12.0%+8.3%+2.0%
Return on capital employed+23.1%+20.0%+18.2%+20.8%+25.0%+21.1%+10.4%
Return on net worth+20.0%+19.1%+19.4%+25.0%+33.0%+20.1%+9.4%
Debt / equity0.270.450.861.011.061.111.19
Long-term debt / equity0.100.190.340.380.360.390.42
Interest cover11.0616.3626.1423.3516.2220.0491.77
Efficiency & per share
Fixed asset turnover1.621.511.501.651.741.491.52
Inventory turnover4.254.574.584.233.953.754.39
Debtors turnover4.034.093.804.054.213.844.77
EPS (₹)48.7635.9627.5029.4236.6223.154.62
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)261.09234.65162.97138.30109.90125.68105.72
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,4511,4681,4181,2611,0971,2781,0291,105
Revenue growth (YoY)+32.3%+14.8%+37.9%+14.1%+13.0%+41.6%+18.2%+24.4%
Other income25.0334.5213822.7521.5222.4019.4149.06
Total expenses1,1111,0961,1471,0368721,034904947
EBITDA340372271225224245124158
EBITDA margin+23.4%+25.3%+19.1%+17.8%+20.5%+19.1%+12.1%+14.3%
Depreciation63.1763.0462.1461.7459.8256.9156.6556.34
Interest32.7836.8733.1527.7120.5424.0719.9331.40
Profit before tax26930631415816618667.24119
Tax68.5772.5755.5140.2742.8846.4917.0532.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,2434,3823,4983,1073,3873,1542,376
Revenue growth+13.0%+22.6%+14.6%+3.2%+6.8%+21.6%+4.1%
Other income312142138125133112138
Total expenses4,2463,7593,0652,6752,5932,4291,996
Employee cost821782706649604551545
EBITDA998623433432795725379
EBITDA margin+19.0%+14.2%+12.4%+13.9%+23.5%+23.0%+16.0%
Depreciation247225205179166156155
Interest118113166167145123137
Profit before tax944428200212616557225
Tax21111139.0852.2717013749.47
Net profit752268162165447434208
Net profit margin+14.3%+6.1%+4.7%+5.3%+13.2%+13.8%+8.8%
EPS (₹)38.6616.748.888.8524.7123.259.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital190189181181181181181
Reserves & surplus3,5212,8351,7541,6611,5322,1211,734
Shareholders' funds (net worth)3,7113,0241,9351,8421,7132,3021,915
Secured loans8102511,4161,6691,5791,5971,191
Unsecured loans7876061801040.0067.1852.59
Total debt1,5978571,5951,7731,5791,6651,243
Total liabilities5,3723,9383,5933,6673,4264,0113,202
Assets
Gross block3,3233,1542,9532,4722,0312,0131,762
Net block1,7541,7591,7181,4331,1511,2781,166
Capital work in progress12299.11106253239192326
Investments1,424678684690563864408
Inventories1,2071,038770710730622444
Sundry debtors1,5351,1911,1031,0541,0099991,138
Cash & bank balances16.8813.8032.1214147.8826139.22
Loans & advances283218218234354334186
Total current assets3,0412,4602,1232,1402,1422,2151,808
Total current liabilities1,5381,4521,135919868824637
Net working capital1,5031,0089881,2201,2741,3921,170
Total assets5,3723,9383,5933,6673,4264,0113,202
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(17.53)(88.91)(213)(393)(84.29)(54.35)(225)
Net cash from operating activities424558585505428775385
Net cash from investing activities(947)(438)(173)(271)(394)(836)(169)
Net cash from financing activities526(49.25)(288)(54.52)(343)30.97(45.87)
Net change in cash2.5171.38124180(309)(29.94)170
Closing cash16.8813.8032.1214147.8826139.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.7%+25.3%+12.6%-8.3%+7.4%+32.8%-3.2%
EBITDA growth+60.1%+44.1%+0.1%-45.6%+9.6%+91.2%-29.2%
PBT growth+120.8%+114.0%-5.9%-65.6%+10.6%+148.1%-39.3%
Net income growth+180.4%+65.1%-1.5%-63.1%+3.0%+108.6%-32.9%
Revenue CAGR (3Y)+19.1%+9.0%+3.5%+9.4%+11.4%--
EBITDA CAGR (3Y)+32.1%-7.8%-15.8%+4.5%+14.1%--
Profitability & leverage
Net income margin+14.0%+7.2%+4.6%+5.2%+13.2%+13.3%+7.4%
Return on capital employed+22.8%+14.4%+10.1%+10.7%+20.5%+18.9%+13.1%
Return on net worth+21.8%+12.8%+8.5%+9.0%+22.3%+20.0%+11.3%
Debt / equity0.360.490.890.940.790.690.67
Long-term debt / equity0.220.240.340.340.290.280.26
Interest cover15.7528.3772.9365.7323.0821.6861.18
Efficiency & per share
Fixed asset turnover1.621.441.291.381.731.671.43
Inventory turnover4.674.854.734.315.015.925.06
Debtors turnover3.853.823.243.013.372.952.32
EPS (₹)38.6616.748.888.8524.7123.259.69
Dividend per share (₹)3.603.002.002.003.001.002.50
Book value per share (₹)195.72159.61106.82101.8494.69127.27105.86
Want more history and ratios?
You're viewing the latest exchange-filed financials for Emcure Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Emcure Pharmaceuticals Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 77.80%, foreign institutional investors hold 4.90%, domestic institutional investors hold 8.40%, retail and other public shareholders hold 8.90% of Emcure Pharmaceuticals Limited.

Promoters: 77.80%DII (Domestic Institutional): 8.40%FII (Foreign Institutional): 4.90%Retail & Others: 8.90%
Jun 2026
QUARTER
77.80% Promoters
8.40% DII (Domestic Institutional)
4.90% FII (Foreign Institutional)
8.90% Retail & Others
Promoter holding - history
Now 77.80% · Jun 2026High 77.90% · Sep 2025Low 77.80% · Jun 2026
76%76.8%77.5%78.3%79%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 77.90%Dec 2025: 77.90%Mar 2026: 77.90%Jun 2026: 77.80%77.90%77.80%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters77.80%77.90%77.90%77.90%
Public22.20%22.10%22.10%22.10%

Group Structure of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Emcure Pharmaceuticals Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Gennova Biopharmaceuticals Limited U24231PN2001PLC016253 -
Zuventus Healthcare Limited U85320PN2002PLC018324 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Emcure Pharmaceuticals Limited

Open charges
₹1,655.61 Cr
Satisfied charges
₹7,259.14 Cr
Breakdown by lending institutions
Others₹1,106.00 Cr
Axis Bank Limited₹399.61 Cr
Citi Bank N.A.₹150.00 Cr
Latest charge details
DateLenderAmountStatus
17 Jun 2026 Axis Bank Limited ₹187 Cr Open
18 Dec 2025 Citi Bank N.A. ₹150 Cr Open
19 Sep 2025 Others ₹100 Cr Open
12 Jun 2025 Others ₹250 Cr Open
15 May 2024 Others ₹100 Cr Open

Total charge records: 133 View all charges

Employees and EPFO Compliance at Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has a workforce of 6,877 employees as of Mar 03, 2025.

Employee count
6,877
Active EPFO establishments
10
Employee growth
5.12%
Premium access

Employee and EPFO history for Emcure Pharmaceuticals Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Emcure Pharmaceuticals Limited

Premium access

GST registrations and filing compliance for Emcure Pharmaceuticals Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Emcure Pharmaceuticals Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Emcure Pharmaceuticals Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Emcure Pharmaceuticals Limited

Premium access

MSME payment history for Emcure Pharmaceuticals Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Emcure Pharmaceuticals Limited

Premium access

Corporate group structure for Emcure Pharmaceuticals Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Emcure Pharmaceuticals Limited

Premium access

MCA filings and documents for Emcure Pharmaceuticals Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Emcure Pharmaceuticals Limited

Charges
17 Jun 2026
A charge with Axis Bank Limited amounted to Rs. 187.00 Cr with Charge ID 101322472 was registered on 17 Jun 2026.
Charges
15 May 2026
A charge registered on 22 Apr 2021 via Charge ID 100444576 with Axis Bank Limited was fully satisfied on 15 May 2026.
Charges
22 Apr 2026
A charge with Others of Rs. 100.00 Cr registered on 15 May 2024 with Charge ID 100930339 was modified on 22 Apr 2026.
Charges
18 Apr 2026
A charge registered on 23 Aug 2021 via Charge ID 100482877 with Axis Bank Limited was fully satisfied on 18 Apr 2026.
Charges
17 Apr 2026
A charge with Others of Rs. 275.00 Cr registered on 25 Mar 2022 with Charge ID 100551885 was modified on 17 Apr 2026.
Charges
17 Apr 2026
A charge registered on 02 Mar 2021 via Charge ID 100423851 with Hdfc Bank Limited was fully satisfied on 17 Apr 2026.

Recent News on Emcure Pharmaceuticals Limited

Stocks that will see action today: 6 April, 2025
07 Apr 2025 · Thehindubusinessline

Frequently Asked Questions about Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is an active public limited company in the pharma sector based in Pune City, Maharashtra, India. It was incorporated on 16 April 1981 (45+ years old) and is registered under CIN L24231PN1981PLC024251. The company has 6,877 employees.

Emcure Pharmaceuticals Limited reported revenue of ₹9,203.54 Cr for FY 2025-26 (up 16.56% YoY) based on consolidated financials.

The current directors of Emcure Pharmaceuticals Limited are:

The primary industry of Emcure Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes, Emcure Pharmaceuticals Limited is a listed company.

Emcure Pharmaceuticals Limited can be reached at the registered office: Plot No. P – 1 & P – 2 It – Bt Park, Phase – Ii M.I.D.C, Pune City, Maharashtra, India – 411057, or through the website emcure.co.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available